Schizoaffective disorder
Schizoaffective disorder, also known as schizo-affective psychosis, refers to a group of mental disorders in which schizophrenia symptoms and affective symptoms coexist and are equally prominent. Schizophrenia symptoms are positive psychotic symptoms such as hallucinations, delusions and thought disorders, and affective symptoms are symptoms of manic episodes or depressive episodes.
-
Site of disease:
psychology -
Infectious :
Not contagious -
Frequent population:
The age of onset is more common in young and middle-aged people, and women... -
Related symptoms:
Depression mania schizoid personality disorder hallucinations -
Concurrent disease:
Related Drugs
PALIPERIDONE_- paliperidone_tablet, extended release
Indication: Paliperidone is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1. 2 Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14. 1 paliperidone extended-release tablets Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14.
Manufacturer:
NorthStar RxLLC
INVEGA SUSTENNA- paliperidone palmitate_injection
Indication: INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14. 1) Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants [see Clinical Studies (14. 2) INVEGA SUSTENNA is an atypical antipsychotic indicated for Treatment of schizophrenia in adults. ( 1 Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Manufacturer:
Janssen Pharmaceuticals, Inc.
PALIPERIDONE- paliperidone_tablet, extended release
Indication: Paliperidone is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1. 1 Adults: Efficacy was established in three 6-week trials and one maintenance trial. 1 Adolescents (ages 12-17): Efficacy was established in one 6-week trial. 1 Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants ( 1. 2 Efficacy was established in two 6-week trials in adult patients ( 14. 2 Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14. 1) The efficacy of paliperidone in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14. 2) The efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults.
Manufacturer:
ANI Pharmaceuticals, Inc.
ERZOFRI EXTENDED-RELEASE- paliperidone palmitate_injection
Indication: ERZOFRI is indicated for the treatment of: Schizophrenia in adults. Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants. ERZOFRI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Manufacturer:
Shandong Luye Pharmaceutical Co., Ltd.
PALIPERIDONE- paliperidone_tablet, extended release
Indication: Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia (1. 1) Adults: Efficacy was established in three 6-week trials and one maintenance trial. 1) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. 1) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. 2) Efficacy was established in two 6-week trials in adult patients. 2) Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14. 1) The efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14. 2) The efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults.
Manufacturer:
Amneal Pharmaceuticals LLC